Literature DB >> 2621533

Concurrent pancreatic and growth hormone insufficiency in Johanson-Blizzard syndrome.

B K Sandhu1, M J Brueton.   

Abstract

Exocrine pancreatic insufficiency is one of the recognised features of the Johanson-Blizzard syndrome; other features include hypothyroidism, sensorineural deafness, aplastic alae nasi, developmental delay, and growth retardation. Twenty-one cases of the syndrome have been described to date. The child reported here was diagnosed in the neonatal period, but despite early pancreatic and thyroid replacement therapy his growth remained poor. Anterior pituitary function studies demonstrated growth hormone deficiency, subsequent administration of growth hormone has resulted in an improvement in his growth velocity. This feature has not been well documented and should be considered as a factor contributing to the growth retardation which is a constant feature of this syndrome.

Entities:  

Mesh:

Year:  1989        PMID: 2621533     DOI: 10.1097/00005176-198911000-00026

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

1.  Johanson-Blizzard syndrome.

Authors:  Nabeel Almashraki; Mukarram Zainuddin Abdulnabee; Maja Sukalo; Abdullah Alrajoudi; Iman Sharafadeen; Martin Zenker
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Johanson--blizzard syndrome.

Authors:  M L Kulkarni; S K Shetty; K S Kallambella; P M Kulkarni
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

Review 3.  Eponym: Johanson-Blizzard syndrome.

Authors:  Nima Rezaei; Mozhgan Sabbaghian; Zhifeng Liu; Martin Zenker
Journal:  Eur J Pediatr       Date:  2010-06-17       Impact factor: 3.183

4.  Johanson-Blizzard syndrome with mild phenotypic features confirmed by UBR1 gene testing.

Authors:  Naim Alkhouri; Barbara Kaplan; Marsha Kay; Amy Shealy; Carol Crowe; Susanne Bauhuber; Martin Zenker
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.